VolitionRX Innovates Cancer Detection and Expands into Sepsis Diagnostics with New Platforms

VolitionRX Advances Cancer Detection Innovations

VolitionRx Limited, a pioneer in the epigenetics sector, makes notable strides in cancer detection through its cutting-edge Capture-Seq™ platform. The firm, based in Henderson, Nevada, recently submits a groundbreaking paper for peer review that outlines this innovative technology and positions it at the forefront of a potential $23 billion annual market for cancer diagnostics. Capture-Seq™ enables direct analysis of transcription factor protected cell-free DNA (cfDNA) in plasma, providing a pathway for healthcare professionals to identify diseases early and accurately. This advancement not only underscores Volition's technological prowess but also reinforces its commitment to enhancing patient outcomes through non-invasive testing methodologies, thereby addressing critical gaps in current cancer detection protocols.

In parallel to its scientific achievements, VolitionRx pursues regulatory milestones that can accelerate the clinical use of its Nu.Q® Cancer assays. The company is currently working on a reimbursement application in France, targeting routine clinical deployment for lung cancer detection by the fourth quarter of 2026. This initiative benefits significantly from collaborations with major healthcare institutions, including France's second-largest hospital system. By securing reimbursement pathways, VolitionRx sets itself on a strategic trajectory that could facilitate widespread adoption of its diagnostic tests, ultimately contributing to improved patient care and early cancer intervention strategies.

Another significant area of focus for Volition is its advancements in sepsis detection, which have implications for urgent medical needs beyond oncology. The company’s Nu.Q® NETs assay gains recognition through its inclusion in the DETECSEPS initiative—a government-backed program aimed at enhancing sepsis patient care. Funded with approximately $7.3 million, this initiative prioritizes the early detection and tailored treatment of sepsis, a condition that demands rapid response to improve survival rates. By expanding its product applications to include sepsis diagnostics, VolitionRx not only broadens its market reach but also reinforces its role as a key player in critical healthcare advancements.

In addition to these developments, VolitionRx's recent achievement of 100% specificity in detecting Feline Lymphoma has set the company up for a $5 million milestone payment, prompting further interest in its veterinary application of technology. Moreover, VolitionRx actively engages in partnership discussions with about ten major global diagnostic firms to enhance the commercialization of its innovative cancer detection solutions. These partnerships are pivotal for realizing the full potential of Volition's technological innovations, ultimately leading to improved diagnostics that could redefine standards in patient care across multiple medical domains.